New England Capital Financial Advisors LLC Gilead Sciences, Inc. Transaction History
New England Capital Financial Advisors LLC
- $193 Billion
- Q3 2024
A detailed history of New England Capital Financial Advisors LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, New England Capital Financial Advisors LLC holds 674 shares of GILD stock, worth $59,365. This represents 0.03% of its overall portfolio holdings.
Number of Shares
674
Previous 670
0.6%
Holding current value
$59,365
Previous $46 Million
22.82%
% of portfolio
0.03%
Previous 0.03%
Shares
8 transactions
Others Institutions Holding GILD
# of Institutions
1,893Shares Held
1.02BCall Options Held
12MPut Options Held
9.04M-
Black Rock Inc. New York, NY121MShares$10.6 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$10.2 Billion0.15% of portfolio
-
Capital World Investors Los Angeles, CA76.2MShares$6.72 Billion0.88% of portfolio
-
Capital Research Global Investors Los Angeles, CA60.4MShares$5.32 Billion0.94% of portfolio
-
State Street Corp Boston, MA59.3MShares$5.23 Billion0.18% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $110B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...